Q2 2025 Bausch Health Companies Inc Earnings Call Transcript
Key Points
- Bausch Health Companies Inc (BHC) reported its ninth consecutive quarter of revenue and adjusted EBITDA growth, with a 5% year-over-year revenue increase and a 10% rise in adjusted EBITDA.
- The company achieved double-digit revenue growth in its Salix, Solta, EMEA, and Canada segments, demonstrating strong performance across diverse markets.
- BHC successfully completed a $7.9 billion debt refinancing, extending maturities and improving its capital structure.
- The acquisition of DURECT Corporation is expected to enhance BHC's hepatology expertise and expand its treatment offerings for alcohol hepatitis.
- BHC's strategic partnership with YUN NV aims to introduce innovative microbiome skincare solutions, potentially reshaping the skincare market.
- Adjusted gross margin decreased by 30 basis points year-over-year, indicating potential pressure on profitability.
- The LATAM region experienced softer performance due to macroeconomic challenges and channel destocking.
- Revenue in the diversified segment decreased by 13% compared to the previous year, driven by declines in neurology and dermatology businesses.
- The ongoing negotiations with CMS regarding Xifaxan's pricing under the Inflation Reduction Act could lead to significant price reductions, impacting future revenue.
- Solta's growth in China was modest at 4% due to tariff-related headwinds, indicating potential challenges in maintaining growth in this market.
Welcome to the Bausch Health first-quarter (sic - second-quarter) 2025 earnings call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to our host, Garen Sarafian, Investor Relations at Bausch. You may begin.
Good afternoon and welcome to Bausch Health's second-quarter 2025 earnings conference call. Participating in today's call are Thomas Appio, Chief Executive Officer of Bausch Health; and JJ Charhon, Chief Financial Officer.
Before we begin, I would like to remind you that our presentation today contains forward-looking information. We ask you to take a moment to read the forward-looking statements disclaimer at the beginning of the pages that accompany this presentation, as it contains important information.
Our actual results may vary materially from those expressed or implied in our forward-looking statements, and you should not place undue reliance on any forward-looking statements. Please refer to our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
